OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
The US Food and Drug Administration recently approved REBLOZYL® (luspatercept-aamt), the first and only erythroid maturation agent (EMA) indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of […]
Read More...Released: November 14, 2019 The U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma usually responds well to initial treatment, but eventually returns or stops responding, and the cancer cells continue […]
Read More...Merck is pleased to announce the availability of a new pack for KEYTRUDA® (pembrolizumab)Injection 100 mg/4 mL (25 mg/mL) (“KEYTRUDA”).The new pack contains two 100mg/4 mL single-dose vials in a single carton. The price per vial of KEYTRUDA is not affected by the introduction of this new pack. The National Drug Code (NDC) for this […]
Read More...Join OSCO for the Official Best of San Antonio Breast Cancer Symposium® designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease.
Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at [email protected] or by phone at 405-850-8334.
The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.
